Research programme: anti-CD137 monoclonal antibodies - Nanjing Galaxy Biopharmaceutical

Drug Profile

Research programme: anti-CD137 monoclonal antibodies - Nanjing Galaxy Biopharmaceutical

Alternative Names: anti-CD137 monoclonal antibodies – Nanjing Galaxy Biopharmaceutical; anticancer antibodies – Nanjing Galaxy Biopharmaceutical

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Nanjing Galaxy Biopharmaceutical
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Apr 2017 Preclinical trials in Cancer in China prior to April 2017 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top